Open AccessEfficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
Author(s) -
Guanghui Gao,
Jun Zhao,
Shengxiang Ren,
Yina Wang,
Gongyan Chen,
Jianhua Chen,
Kangsheng Gu,
Renhua Guo,
Yueyin Pan,
Quanren Wang,
Weixia Li,
Xinfeng Yang,
Caicun Zhou
Publication year - 2022
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-21-4792
Subject(s) - apatinib , medicine , oncology , response evaluation criteria in solid tumors , lung cancer , clinical endpoint , regimen , progression free survival , cohort , cancer , chemotherapy , progressive disease , surgery , gastroenterology , clinical trial
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom